echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Berkeley Lights acquires IsoPlexis and merges to create a state-of-the-art functional cell biology company

    Berkeley Lights acquires IsoPlexis and merges to create a state-of-the-art functional cell biology company

    • Last Update: 2023-02-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Berkeley Lights (Nasdaq: BLI), a leading life sciences company, and single-cell proteomics expert IsoPlexis (Nasdaq: ISO) recently announced a definitive agreement under which Berkeley Lights will acquire IsoPlexis
    in an all-stock transaction.

    Berkeley Lights will acquire IsoPlexis in an all-stock transaction

    Berkeley Headquartered in Emeryville, California, Lights is a leading digital cell biology company
    focused on single-cell functional characterization solutions.
    Based on proprietary light guide technology and nano-microfluidic technology, BLI provides scientists with the most advanced research environment to conduct in-depth characterization of the genetic information and function of tens of thousands of single cells to screen out the target cells
    that meet the needs of users 。 Berkeley Since its launch in 2016, Lights' single-cell light guide platform has more than 100 users around the world, covering infectious disease research, emergency medicine, cell line development, vaccine production, immunology research and cell therapy development, gene editing, tumor biology research, stem cell function characterization, gene therapy development, synthetic biology and agricultural science, providing unprecedented opportunities to engage in cutting-edge scientific research projects and accelerate the development of enterprise biological products

    A leading digital cell biology company specializing in single-cell functional characterization solutions for infectious disease research, emergency medicine, cell line development, vaccine production, immunology research and cell therapy development, gene editing, tumor biology research, stem cell function characterization, gene therapy development, synthetic biology, and agricultural science

    After the acquisition, Berkeley Lights and IsoPlexis will merge to form a new company
    called PhenomeX (Nasdaq: CELL).
    As a leading explorer of functional cell biology, PhenomeX will bring together innovative solutions from both companies and a global team that complements our corporate culture and business capabilities, and through its leading technology in functional cell biology, it will provide researchers with live-cell biology research tools, presenting in-depth insights into cell function and new perspectives
    on various research phenomena.

    The merger to form a new company called PhenomeX (Nasdaq: CELL) will bring together innovative solutions from both companies

    The acquisition is expected to close
    in the first quarter of 2023.
    Until the acquisition closes, Berkeley Lights and IsoPlexis will continue to operate
    as two separate companies.

    Since IsoPlexis entered China, it has received strong support from customers and partners! We will adhere to the original intention of serving Chinese customers, continue to provide you with high-quality single-cell functional protein detection solutions, and jointly explore superheroes in single-cell cells!

    Original English: https://endpts.
    com/berkeley-lights-to-acquire-isoplexis-in-57-8m-all-stock-deal/

    https://endpts.
    com/berkeley-lights-to-acquire-isoplexis-in-57-8m-all-stock-deal/
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.